Silvina
Silvina L. Cacia, Ezequiel J. Zaidel Niveles en neonatos: Se estima que la dosis promedio que reciben los lactantes amamantados es entre 0,004 % y 0,07 % de la dosis materna. En algunos reportes de casos se hallaron niveles entre 0 y 21 mcg/L (20-22). Discusión Como se ha observado, actualmente se acepta el uso de labetalol en diferentes condiciones CV de gineco-obstetricia. Sin embargo, la evidencia para su uso proviene de pequeños ensayos clínicos aleatorizados con críticas metodológicas publicados hasta el año 1990 aproximadamente, y de análisis retrospectivos de grandes bases de datos más recientes, pero que no dejan de presentar sesgos de selección por su evaluación retrospectiva incluso a pesar de realizar ajustes a múltiples variables. Por ello, es imperioso continuar la investigación y desarrollo de fármacos cardiovasculares en estas condiciones, así como el desarrollo de estudios pragmáticos con los fármacos ya existentes. Conclusiones Hemos revisado la información publicada a la fecha, y pudimos comprobar que el labetalol es una herramienta esencial para el manejo de las complicaciones CV durante el embarazo y puerperio. Los especialistas de ginecología y obstetricia deberían actualizarse periódicamente en los aspectos farmacológicos y terapéuticos del labetalol. Referencias bibliográficas • 1. Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-476. doi:10.1016/j. jacc.2018.10.075. • 2. Kaplan’s Essentials of Cardiac Anesthesia, 2nd edition 2018 978-0-323- 49798-5 https://doi.org/10.1016/C2012- 0-06151-0. • 3. El-Borm, H.T., Atallah, M.N. Protective effects of Zingiber officinale extract on myocardium and placenta against labetalol-induced histopathological, immune-histochemical, and ultrastructural alterations in pregnant rats. JoBAZ 82, 38 (2021). https://doi.org/10.1186/s41936- 021-00238-7. • 4. Thulesius O, Lunell NO, Ibrahim M, Moberger B, Angilivilayil C. The effect of labetalol on contractility of human myometrial preparations. Acta Obstet Gynecol Scand. 1987;66(3):237-240. doi:10.3109/00016348709020754. • 5. Rogers R.C., Sibai B.M. and Whybrew W.D.: “Labetalol pharmacokinetics in pregnancy-induced hypertension”. Am J Obstet Gynecol 1990; 162: 362. • 6. Amro F.H., Moussa H.N., Ashimi O.A. and Sibai B.M.: “Treatment options for hypertension in pregnancy and puerperium”. Expert Opin Drug Saf 2016; 15: 1635. • 7. Fischer J.H., Sarto G.E., Hardman J.et al.: “Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy”. Clin Pharmacokinet 2014; 53: 373. • 8. Khatri R, Fallon JK, Sykes C, et al. Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes. Front Pharmacol. 2021;12:655320. Published 2021 Apr 15. doi:10.3389/fphar.2021.655320. • 9. American College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy : “Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy”. Obstet Gynecol 2013; 122: 1122. • 10. Lardoux H, Gerard J, Blazquez G, Chouty F, Flouvat B. Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. Eur Heart J. 1983;4 Suppl G:35-40. doi:10.1093/eurheartj/4. suppl_g.35. • 11. Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. b-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4):e001185. Published 2012 Jul 19. doi:10.1136/bmjopen-2012-001185. • 12. Lee MS, Chen W, Zhang Z, et al. Atrial Fibrillation and Atrial Flutter in Pregnant Women-A Population-Based Study. J Am Heart Assoc. 2016;5(4):e003182. Published 2016 Apr 13. doi:10.1161/ JAHA.115.003182. • 13. Barbieri C, Larovere MT, Mariotti G, et al. Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf). 1982;16:615–9. • 14. McGuinness N, Cording V. Raynaud’s phenomenon of the nipple associated with labetalol use. J Hum Lact. 2013;29:17–9. • 15. Avila-Vega J, Urrea-Mendoza E, Lee C. Raynaud’s phenomenon of the nipple as a side-effect of labetalol: Case report and literature review. Case Rep Womens Health. 2019;23:e00135. • 16. Sharma KJ, Greene N, Kilpatrick SJ. Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial. Hypertens Pregnancy. 2017;36(1):44-47. doi:10.1080/106419 55.2016.1231317. • 17. Vigil-De Gracia P, Ruiz E, López JC, de Jaramillo IA, Vega-Maleck JC, Pinzón J. Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial. Hypertens Pregnancy. 2007;26(2):163-171. doi:10.1080/10641950701204430. • 18. Riant P, Urien S, Albengres E, et al. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986;35:4579–81. • 19. Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol. 1979;8 Suppl 2:211S–5S. • 20. Leitz F, Bariletto S, Gural R, et al. Secretion of labetalol in breast milk of lactating women. Fed Proc. 1983;42:378. Abstract. • 21. Lunell NO, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol. 1985;28:597–9. • 22. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk: Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1988;14:217–40. 14 // EDITORIAL SCIENS
